Q32 Bio And Horizon Therapeutics Have Dosed The First Patient In Phase 2 Study Of Bempikibart In Adult Patients With Severe Alopecia Areata
Portfolio Pulse from Benzinga Newsdesk
Q32 Bio and Horizon Therapeutics have dosed the first patient in a Phase 2 study of bempikibart in adult patients with severe alopecia areata. The companies are collaborating to develop bempikibart, an anti-IL-7Rα antibody that re-regulates adaptive immune function.
September 13, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Horizon Therapeutics is collaborating with Q32 Bio to develop bempikibart, which has entered Phase 2 trials. This could potentially lead to a new treatment option for severe alopecia areata.
The news of Horizon Therapeutics entering Phase 2 trials for a potential new treatment is directly relevant to the company and could have a positive impact on its stock price in the short term. The success of the trials could potentially open up a new revenue stream for the company.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100